Q-Med AB: Interim report January-September 2010

- Group revenues from sales of goods and royalties amounted to 1,060 (1,016)
MSEK.

- Earnings per share amounted to 1.76 (6.38) SEK.

- Operating income amounted to 245 (676) MSEK.

- Revenues within the Esthetics product area amounted to 963 (846) MSEK and
operating income was 245 (195) MSEK.

- Net income after tax amounted to 176 (634) MSEK. Net income for 2009 was
positively affected by a total of 505 MSEK as a result of a one-time revenue and
revenues from the research collaboration with Oceana Therapeutics.

July - September
- Group revenues from sales of goods and royalties amounted to 304 (295) MSEK
during the third quarter and operating income amounted to 57 (51) MSEK. For the
Esthetics product area operating income amounted to 69 (53) MSEK and for the
Hospital Healthcare product area operating income amounted to 6 (18) MSEK.

- Net income after tax amounted to 37 (42) MSEK during the third quarter.

- On September 1 Maria Carell took up her appointment as CEO and Bengt Ågerup
became the Chairman of the Board.

- On September 17 Q-Med announced that the application for Premarket Approval,
PMA, for Solesta(TM) in the USA will be discussed on December 2 at a public
meeting with the FDA's Gastroenterology and Urology Devices Panel.

Important events after the end of the period
- Medicis has received notice that Genzyme Corporation has filed a lawsuit
against the company alleging that Medicis is infringing on a patent held by
Genzyme by marketing Restylane, Perlane, Restylane-L and Perlane-L.


Q-Med AB is a medical device company that develops, manufactures, markets, and
sells high quality medical implants for esthetic and medical use. The majority
of the products are based on the company's patented technology, NASHA(TM), for
the production of stabilized non-animal hyaluronic acid. The product portfolio
today contains: Restylane® for filling lines and folds, contouring and creating
volume in the face, Macrolane(TM) for body contouring, Durolane(TM) for the
treatment of osteoarthritis of the hip and knee joints, Deflux® for the
treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder)
in children, and Solesta® for the treatment of fecal incontinence. Sales are
made through the company's own subsidiaries or distributors in over 70
countries. Q‑Med today has about 650 coworkers, with almost 400 at the company's
head office and production facility in Uppsala, Sweden. Q-Med AB is listed in
the Mid Cap segment of the NASDAQ OMX Nordic.


Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate
identity number 556258-6882.
Tel: +46 18 474 90 00. Fax: +46 18 474 90 01. E-mail:info@q-med.com. Web: www.q-
med.com.

The full report with tables can be downloaded from the following link:


[HUG#1454282]